Charles River Laboratories International (NYSE:CRL) Upgraded at Bank of America

Bank of America upgraded shares of Charles River Laboratories International (NYSE:CRL) from a neutral rating to a buy rating in a research note published on Monday morning, MarketBeat reports. The brokerage currently has $225.00 target price on the medical research company’s stock.

Several other equities analysts have also recently issued reports on CRL. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a report on Monday, December 1st. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Barclays boosted their price target on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday. Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Mizuho lifted their target price on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $194.07.

Charles River Laboratories International Trading Up 0.3%

Shares of NYSE CRL opened at $195.73 on Monday. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $200.58. The company has a 50-day moving average of $178.81 and a two-hundred day moving average of $164.72. The company has a market cap of $9.63 billion, a PE ratio of -125.47, a P/E/G ratio of 6.90 and a beta of 1.63. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. During the same quarter last year, the business posted $2.59 earnings per share. Charles River Laboratories International’s revenue for the quarter was down .5% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock valued at $913,686,000 after purchasing an additional 27,989 shares in the last quarter. Wellington Management Group LLP lifted its stake in Charles River Laboratories International by 5.1% in the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock valued at $644,980,000 after buying an additional 208,586 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 29.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after buying an additional 516,521 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of Charles River Laboratories International by 8.0% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock worth $293,555,000 after acquiring an additional 144,732 shares in the last quarter. Finally, Ariel Investments LLC raised its holdings in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after acquiring an additional 314,572 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).